JP2019524802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524802A5 JP2019524802A5 JP2019507107A JP2019507107A JP2019524802A5 JP 2019524802 A5 JP2019524802 A5 JP 2019524802A5 JP 2019507107 A JP2019507107 A JP 2019507107A JP 2019507107 A JP2019507107 A JP 2019507107A JP 2019524802 A5 JP2019524802 A5 JP 2019524802A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- liposome
- polyglutamine
- lpa
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 239000002502 liposome Substances 0.000 claims 27
- 239000004052 folic acid antagonist Substances 0.000 claims 14
- 108010040003 polyglutamine Proteins 0.000 claims 12
- 229920000155 polyglutamine Polymers 0.000 claims 12
- 230000003432 anti-folate effect Effects 0.000 claims 11
- 229940127074 antifolate Drugs 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 230000003647 oxidation Effects 0.000 claims 6
- 238000007254 oxidation reaction Methods 0.000 claims 6
- 229960005079 pemetrexed Drugs 0.000 claims 5
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 102000010449 Folate receptor beta Human genes 0.000 claims 4
- 108050001930 Folate receptor beta Proteins 0.000 claims 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 238000001125 extrusion Methods 0.000 claims 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229960000485 methotrexate Drugs 0.000 claims 4
- 230000001590 oxidative effect Effects 0.000 claims 4
- 229920002643 polyglutamic acid Polymers 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- 229920002498 Beta-glucan Polymers 0.000 claims 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims 3
- 102100023119 Sperm-egg fusion protein Juno Human genes 0.000 claims 3
- 101710093389 Sperm-egg fusion protein Juno Proteins 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- -1 anionic lipid Chemical class 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 102000006815 folate receptor Human genes 0.000 claims 3
- 108020005243 folate receptor Proteins 0.000 claims 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920002401 polyacrylamide Polymers 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229920006187 aquazol Polymers 0.000 claims 1
- 239000012861 aquazol Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 239000001639 calcium acetate Substances 0.000 claims 1
- 229960005147 calcium acetate Drugs 0.000 claims 1
- 235000011092 calcium acetate Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018363A JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374458P | 2016-08-12 | 2016-08-12 | |
| US62/374,458 | 2016-08-12 | ||
| US201715675695A | 2017-08-11 | 2017-08-11 | |
| US15/675,695 | 2017-08-11 | ||
| US15/675,701 | 2017-08-11 | ||
| US15/675,701 US20180236098A1 (en) | 2016-08-12 | 2017-08-11 | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| PCT/US2017/046666 WO2018031979A1 (en) | 2016-08-12 | 2017-08-12 | Alpha and gamma-d polyglutamated antifolates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018363A Division JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524802A JP2019524802A (ja) | 2019-09-05 |
| JP2019524802A5 true JP2019524802A5 (enExample) | 2020-09-24 |
| JP7227123B2 JP7227123B2 (ja) | 2023-02-21 |
Family
ID=65235618
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507107A Active JP7227123B2 (ja) | 2016-08-12 | 2017-08-12 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2019529465A Active JP7576816B2 (ja) | 2016-08-12 | 2017-08-12 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2022100445A Active JP7733390B2 (ja) | 2016-08-12 | 2022-06-22 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2023018363A Active JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A Pending JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2025001190A Pending JP2025072362A (ja) | 2016-08-12 | 2025-01-06 | ポリグルタミン酸化抗葉酸剤およびその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529465A Active JP7576816B2 (ja) | 2016-08-12 | 2017-08-12 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2022100445A Active JP7733390B2 (ja) | 2016-08-12 | 2022-06-22 | ポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2023018363A Active JP7538268B2 (ja) | 2016-08-12 | 2023-02-09 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2024131755A Pending JP2024160315A (ja) | 2016-08-12 | 2024-08-08 | αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用 |
| JP2025001190A Pending JP2025072362A (ja) | 2016-08-12 | 2025-01-06 | ポリグルタミン酸化抗葉酸剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US11344628B2 (enExample) |
| EP (3) | EP3496757A4 (enExample) |
| JP (6) | JP7227123B2 (enExample) |
| KR (6) | KR102708209B1 (enExample) |
| CN (3) | CN109689104A (enExample) |
| AU (4) | AU2017308159B2 (enExample) |
| CA (3) | CA3033077C (enExample) |
| EA (1) | EA201990473A1 (enExample) |
| MX (5) | MX2019001755A (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3496757A4 (en) | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | POLYGLUTAMATE ANTIFOLATES AND USES THEREOF. |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| CA3090506A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| WO2019157145A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3749317A4 (en) * | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| EP3749321A4 (en) * | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CA3090989A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3752158A4 (en) | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
| WO2019160735A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| CA3149914A1 (en) * | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| CN112010862B (zh) * | 2020-10-23 | 2021-03-30 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法 |
| EP4497004A1 (en) * | 2022-03-21 | 2025-01-29 | Immundiagnostik AG | Kit of parts and microbiological method for assessment of the folate status in serum and red blood cells |
| CN115626928B (zh) * | 2022-10-13 | 2023-11-17 | 南京诺源医疗器械有限公司 | 一种靶向α型叶酸受体的培美近红外荧光分子作为荧光示踪剂的用途 |
| JP2024060824A (ja) * | 2022-10-20 | 2024-05-07 | プレミアアンチエイジング株式会社 | 経口製剤及びその製造方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2564319A1 (fr) | 1984-05-21 | 1985-11-22 | Inst Nat Sante Rech Med | Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees |
| US4584375A (en) * | 1984-08-21 | 1986-04-22 | Rensselaer Polytechnic Institute | Fluorine-containing antifolates incapable of polyglutamate formation |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0492316A1 (en) | 1990-12-14 | 1992-07-01 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic oligoglutamate derivatives, their production and pharmaceutical compositions containing them |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| US5997915A (en) | 1996-01-31 | 1999-12-07 | South Alabama Medical Science Foundation | Compositions for human and animal consumption containing reduced folates and methods for making and using same |
| US5912251A (en) | 1998-01-17 | 1999-06-15 | Nair; Madhavan G. | Metabolically inert anti-inflammatory and anti-tumor antifolates |
| US20050031679A1 (en) | 1998-03-27 | 2005-02-10 | Clemens Unger | Method for producing liposomal formulations of active ingredients |
| JP2002520431A (ja) | 1998-07-09 | 2002-07-09 | ロディア・シミ | 水溶性又は水分散性グラフト共重合体 |
| WO2001005405A1 (en) * | 1999-07-16 | 2001-01-25 | The General Hospital Corporation | Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| WO2001053331A2 (en) | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Peptidomimetic modulators of cell adhesion |
| CN1095472C (zh) | 2000-04-17 | 2002-12-04 | 上海复康医药科技发展有限公司 | 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物 |
| AU7526901A (en) | 2000-06-09 | 2001-12-24 | Gilead Sciences Inc | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| DE60127970T2 (de) | 2000-06-30 | 2007-12-20 | Eli Lilly And Co., Indianapolis | Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält |
| US20050163832A1 (en) | 2002-02-13 | 2005-07-28 | Vladimir Torchilin | Intracellular delivery of therapeutic agents |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| US7563590B2 (en) | 2002-08-30 | 2009-07-21 | Cypress Bioscience Inc. | Methods of quantifying methotrexate metabolites |
| US6921667B2 (en) * | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
| US20060240090A1 (en) | 2003-04-02 | 2006-10-26 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| WO2005070465A2 (en) * | 2004-01-14 | 2005-08-04 | Gilead Sciences, Inc. | Lipid-based dispersions useful for drug delivery |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| US7612071B2 (en) | 2004-03-12 | 2009-11-03 | Syntrix Biosystems, Inc. | Compositions and methods employing aminopterin |
| WO2005103250A1 (ja) | 2004-04-26 | 2005-11-03 | Takami Matsuyama | 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬 |
| RU2424792C2 (ru) | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| US7695908B2 (en) * | 2004-06-15 | 2010-04-13 | Prometheus Laboratories Inc. | Methods for predicting methotrexate polyglutamate levels using pharmacogenetics |
| AU2005282241B2 (en) | 2004-09-08 | 2011-03-03 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| EP1797882A4 (en) | 2004-09-29 | 2009-11-18 | Kowa Co | PREVENTIVE AND / OR THERAPEUTIC MEDICAMENT FOR RHEUMATOID ARTHRITIS |
| US8126089B2 (en) | 2004-09-30 | 2012-02-28 | Alcatel Lucent | Method and apparatus for providing frame synchronization in a digital communication system that supports multiple modulation formats |
| US20100266709A1 (en) | 2004-12-16 | 2010-10-21 | Hicks Terry Lee | Compositions and Methods for Treating Burns |
| WO2006074416A1 (en) * | 2005-01-07 | 2006-07-13 | Health Research Inc. | 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| GB2424837B (en) | 2005-04-06 | 2010-10-06 | Cilag Ag Int | Injection device |
| WO2007023243A2 (en) | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Cleavage of antifolate compounds |
| CN101365424A (zh) | 2005-12-08 | 2009-02-11 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 通过超声辐射改变脂质体组成的方法 |
| WO2007098089A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
| US9265746B2 (en) | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
| WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| RU2423114C2 (ru) * | 2006-12-29 | 2011-07-10 | Тракон Фармасьютикалз, Инк. | Комбинации антифолатного агента в лечении рака |
| BRPI0722053A2 (pt) * | 2006-12-29 | 2018-04-17 | Tracon Pharmaceuticals Inc | método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina |
| KR20090113295A (ko) | 2007-01-19 | 2009-10-29 | 첼시 쎄라퓨틱스, 인코포레이티드 | 새로운 유형의 항엽산제 |
| WO2009115776A1 (en) | 2008-03-18 | 2009-09-24 | Btg International Limited | Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia |
| GB0811360D0 (en) | 2008-06-20 | 2008-07-30 | Imp Innovations Ltd | Methods |
| US8609642B2 (en) | 2009-06-03 | 2013-12-17 | Ex-Tek, Llc | Skin treatment compositions |
| TW201118098A (en) | 2009-08-13 | 2011-06-01 | Reddy S Lab Liimited Dr | Processes for preparing pemetrexed |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US8747869B2 (en) | 2010-03-19 | 2014-06-10 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| US9770414B2 (en) * | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| WO2011150392A1 (en) | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| EP2614084A4 (en) | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| WO2012037068A1 (en) * | 2010-09-13 | 2012-03-22 | De Novo Diagnostics, Inc. | Methods for monitoring methotrexate therapy |
| WO2012061469A2 (en) | 2010-11-02 | 2012-05-10 | Sicor Inc. | Crystalline forms of pralatrexate |
| SG189957A1 (en) | 2010-11-05 | 2013-06-28 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| WO2012078708A1 (en) | 2010-12-07 | 2012-06-14 | Chelsea Therapeutics, Inc. | Combination comprising methotrexate and an antifolate compound |
| WO2012118806A2 (en) | 2011-02-28 | 2012-09-07 | The Regents Of The University Of California | Compositions and methods for detecting and treating cancer |
| US9000003B2 (en) | 2011-03-10 | 2015-04-07 | National Science And Technology Development Agency | Anti-folate antimalarials with dual-binding modes and their preparation |
| US8673914B2 (en) | 2011-03-28 | 2014-03-18 | St. John's University | Use of phosphodiesterase inhibitors for treating multidrug resistance |
| EP2508894A1 (en) | 2011-04-05 | 2012-10-10 | Receptomon LLC | Method for monitoring gene expression of translation and Integral/Secretory protein synthesis by magnetic resonance spectroscopy (MRS) |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| HRP20201465T1 (hr) | 2011-07-13 | 2021-02-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomi koji ko-inkapsuliraju bisfosfonat i amfipatsko sredstvo |
| SI2731972T1 (en) | 2011-07-15 | 2018-04-30 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| US20130122096A1 (en) | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
| JPWO2014003137A1 (ja) | 2012-06-27 | 2016-06-02 | 旭化成メディカル株式会社 | 高アフィニティー抗体、及びその製造方法 |
| WO2014016740A2 (en) | 2012-07-23 | 2014-01-30 | Fresenius Kabi Oncology Ltd. | Improved process for the preparation of pralatrexate |
| US20140120157A1 (en) | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
| WO2014046630A1 (en) | 2012-09-19 | 2014-03-27 | Keskin, Dilek | Tumor targeted liposomal drug delivery system |
| CN104884617B (zh) | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | 抗folr1抗体 |
| CN103040748B (zh) * | 2012-12-18 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种培美曲塞二钠脂质体注射剂 |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| US20140363451A1 (en) | 2013-05-14 | 2014-12-11 | Immunogen, Inc. | Anti-FOLR1 Immunoconjugate Dosing Regimens |
| WO2016025882A2 (en) | 2014-08-14 | 2016-02-18 | L.E.A.F Holdings Group Llc. | Liposome encapsulated affinity drug |
| CN104546723B (zh) * | 2015-02-11 | 2017-07-18 | 上海交通大学医学院附属新华医院 | 一种培美曲塞脂质体及其制备方法 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| KR20190003630A (ko) | 2016-04-29 | 2019-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 악성 뇌 종양에서의 표적화된 입자 침투, 분포, 및 반응을 위한 조성물 및 방법 |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3496757A4 (en) | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | POLYGLUTAMATE ANTIFOLATES AND USES THEREOF. |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| WO2019094648A1 (en) | 2017-11-08 | 2019-05-16 | L.E.A.F. Holdings Group Llc | Platinum complexes and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090506A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3749321A4 (en) | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| WO2019157145A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| EP3749317A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CA3090989A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3752158A4 (en) | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
| WO2019160735A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| KR102765012B1 (ko) | 2019-05-27 | 2025-02-07 | 삼성디스플레이 주식회사 | 표시 장치 |
| CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
-
2017
- 2017-08-12 EP EP17840397.8A patent/EP3496757A4/en active Pending
- 2017-08-12 KR KR1020237032981A patent/KR102708209B1/ko active Active
- 2017-08-12 MX MX2019001755A patent/MX2019001755A/es unknown
- 2017-08-12 MX MX2019001756A patent/MX2019001756A/es unknown
- 2017-08-12 CA CA3033077A patent/CA3033077C/en active Active
- 2017-08-12 KR KR1020197005253A patent/KR102584446B1/ko active Active
- 2017-08-12 CN CN201780052159.XA patent/CN109689104A/zh active Pending
- 2017-08-12 JP JP2019507107A patent/JP7227123B2/ja active Active
- 2017-08-12 EA EA201990473A patent/EA201990473A1/ru unknown
- 2017-08-12 AU AU2017308159A patent/AU2017308159B2/en active Active
- 2017-08-12 KR KR1020247030844A patent/KR20240141854A/ko active Pending
- 2017-08-12 CN CN202511392165.2A patent/CN120939250A/zh active Pending
- 2017-08-12 CA CA3177187A patent/CA3177187A1/en active Pending
- 2017-08-12 AU AU2017308158A patent/AU2017308158B2/en active Active
- 2017-08-12 CA CA3033083A patent/CA3033083A1/en active Pending
- 2017-08-12 EP EP22167260.3A patent/EP4052729A1/en active Pending
- 2017-08-12 KR KR1020197006810A patent/KR102585143B1/ko active Active
- 2017-08-12 US US16/324,823 patent/US11344628B2/en active Active
- 2017-08-12 CN CN201780062078.8A patent/CN109789212A/zh active Pending
- 2017-08-12 KR KR1020247030845A patent/KR20240140191A/ko active Pending
- 2017-08-12 KR KR1020237033296A patent/KR102708208B1/ko active Active
- 2017-08-12 EP EP17840396.0A patent/EP3496756A4/en active Pending
- 2017-08-12 JP JP2019529465A patent/JP7576816B2/ja active Active
-
2019
- 2019-02-11 MX MX2023007496A patent/MX2023007496A/es unknown
- 2019-02-11 MX MX2023007726A patent/MX2023007726A/es unknown
- 2019-02-11 MX MX2022009187A patent/MX2022009187A/es unknown
-
2021
- 2021-12-07 US US17/544,182 patent/US12201695B2/en active Active
- 2021-12-07 US US17/544,196 patent/US12178883B2/en active Active
- 2021-12-07 US US17/544,191 patent/US12178882B2/en active Active
-
2022
- 2022-06-22 JP JP2022100445A patent/JP7733390B2/ja active Active
- 2022-07-28 US US17/875,724 patent/US11701432B2/en active Active
-
2023
- 2023-02-09 JP JP2023018363A patent/JP7538268B2/ja active Active
- 2023-05-24 US US18/201,275 patent/US20230381338A1/en not_active Abandoned
- 2023-11-07 AU AU2023263441A patent/AU2023263441B2/en active Active
- 2023-11-07 AU AU2023263442A patent/AU2023263442B2/en active Active
-
2024
- 2024-07-31 US US18/790,916 patent/US20240390514A1/en active Pending
- 2024-08-08 JP JP2024131755A patent/JP2024160315A/ja active Pending
- 2024-09-27 US US18/899,598 patent/US20250127920A1/en active Pending
- 2024-09-30 US US18/902,040 patent/US20250018055A1/en active Pending
- 2024-12-10 US US18/975,339 patent/US20250099608A1/en not_active Abandoned
-
2025
- 2025-01-06 JP JP2025001190A patent/JP2025072362A/ja active Pending
- 2025-03-04 US US19/069,794 patent/US20250195686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524802A5 (enExample) | ||
| JP2019524885A5 (enExample) | ||
| JP7555630B2 (ja) | カロテノイド組成物およびその使用 | |
| JP2017526744A5 (enExample) | ||
| US20220211878A1 (en) | Cross-linked polymer modified nanoparticles | |
| DK2714017T3 (en) | MEMBRANE-WRAPPED NANOPARTICLES AND METHOD OF USE | |
| JPWO2019157145A5 (enExample) | ||
| JPWO2019157138A5 (enExample) | ||
| AU2014218717A1 (en) | Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles | |
| JPWO2019157120A5 (enExample) | ||
| JP6321305B2 (ja) | 薬物送達用ナノ粒子組成物 | |
| Patil-Sen et al. | Nanotechnology: The Future for Cancer Treatment | |
| Thamphiwatana | Antimicrobial Nanotherapeutics Against Helicobacter pylori Infection | |
| EA047345B1 (ru) | Композиция каротиноида и способ ее получения | |
| EP4667017A2 (en) | Carotenoid compositions and uses thereof | |
| HK1243002B (en) | Membrane encapsulated nanoparticles and method of use | |
| Duarte | Determination of the Activity of BNIPS Derivative Compounds Incorporated Into Liposomes Against Pancreatic Tumor Cells | |
| HK1197016B (en) | Membrane encapsulated nanoparticles and method of use |